News FDA panel narrowly backs heart benefit of BI/Lilly diabetes ... FDA advisers voted 12-11 that Jardiance also reduces cardiovascular risks.
News Victoza disappoints on cardio benefits, lifts rival Jardianc... Victoza results are significant, but fell short of investors' expectations.
News Pharma looking to dual-action diabetes drugs to boost sales Pharma using FDA-mandated trials to give a commercial advantage.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
